TerminatedPHASE2, PHASE3NCT01189253
Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma
Studying Alveolar soft tissue sarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
- Principal Investigator
- Nguyen Binh Bui, MDInstitut Bergonié
- Intervention
- doxorubicin hydrochloride(drug)
- Enrollment
- 133 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2011 – 2015
Study locations (30)
- Sarcoma Oncology Center, Santa Monica, California, United States
- Stanford Hospital and Clinics, Stanford, California, United States
- Holden Comprehensive Cancer Center at University of Iowa, Iowa City, Iowa, United States
- Dana Farber Institute, Boston, Massachusetts, United States
- Massachussets General Hospital, Boston, Massachusetts, United States
- Methodist Estabrook Cancer Center, Omaha, Nebraska, United States
- Carolinas Hematology-Oncology Associates, Charlotte, North Carolina, United States
- Pennsylvania Oncology Hematology Associates, Incorporated - Philadelphia, Philadelphia, Pennsylvania, United States
- Medical University Vienna, Vienna, Austria
- HôPITAUX UNIVERSITAIRES BORDET-ERASME - INSTITUT JULES BORDET, Brussels, Belgium
- Cliniques Universitaires St. Luc, Brussels, Belgium
- U.Z. Gasthuisberg, Leuven, Belgium
- Aarhus University Hospital, Aarhus, Denmark
- Herlev Hospital - University Copenhagen, Herlev, Denmark
- Institut Bergonie, Bordeaux, France
- +15 more locations on ClinicalTrials.gov
Collaborators
Sarcoma Alliance for Research through Collaboration
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01189253 on ClinicalTrials.govOther trials for Alveolar soft tissue sarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07548177Clinical Trials of Benmelstobart Injection Combined With Anlotinib Hydrochloride Capsules in the Treatment of Advanced or Unresectable Alveolar Soft Part SarcomaChia Tai Tianqing Pharmaceutical Group Co., Ltd.
- RECRUITINGPHASE1NCT06066138A Study of Therapeutic Drug Monitoring-Based Atezolizumab DosingNational Cancer Institute (NCI)
- ACTIVE NOT RECRUITINGEARLY PHASE1NCT06813417CAR T Therapy With GCAR1 for Relapsed Alveolar Soft Part SarcomaUniversity of Calgary
- ACTIVE NOT RECRUITINGEARLY PHASE1NCT06789081GPNMB-targeting Chimeric Antigen Receptor T-Cell Therapy (GCAR1) for a Patient With Alveolar Soft Part Sarcoma (CLIC-YYC-GPNMB-02)AHS Cancer Control Alberta
- RECRUITINGPHASE2NCT05333458Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, The AXIOM TrialNational Cancer Institute (NCI)
- RECRUITINGNANCT03967834Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - MIRAS Project From SARRA (SARcome RAre) Project of the French Sarcoma GroupInstitut Claudius Regaud
- RECRUITINGPHASE2NCT04332874A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or LegMemorial Sloan Kettering Cancer Center
- RECRUITINGPHASE3NCT03016819Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)Advenchen Laboratories, LLC